Dignitana AB engages in the development, manufacture and marketing of medical technology systems related to medical cooling. The company is headquartered in Lund, Skane and currently employs 25 full-time employees. The company develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The firm focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patient’s head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. The company has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.
Follow-Up Questions
Quelle est la performance du prix de l'action DIZTF ?
Le prix actuel de DIZTF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Dignitana AB ?
Dignitana AB appartient à l'industrie Health Care et le secteur est Health Care
Quelle est la capitalisation boursière de Dignitana AB ?
La capitalisation boursière actuelle de Dignitana AB est de $0
